4,366 results match your criteria Tardive Dyskinesia


Risperidone-Induced Tardive Dyskinesia in an Autistic Child.

Authors:
Vasco Kidd

Prim Care Companion CNS Disord 2018 Dec 6;20(6). Epub 2018 Dec 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.18l02283DOI Listing
December 2018

Tardive dyskinesia: Who gets it and why.

Authors:
Karen Frei

Parkinsonism Relat Disord 2018 Nov 15. Epub 2018 Nov 15.

Loma Linda University, Loma Linda, CA, USA. Electronic address:

Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of antipsychotic agent, being greater for those of first generation antipsychotics (FGA), the duration of illness and cumulative dose of DRBA and advanced age. Female sex and African and Caucasian ethnicity are additional potential risk factors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183051
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.017DOI Listing
November 2018
1 Read

[Extrapyramidal adverse reactions to metoclopramide. A pharmacovigilance survey].

Rev Med Chil 2018 Jul;146(7):876-884

Servicio de Farmacia, Hospital La Ligua, La Ligua, Chile.

Background: In 2013 the Chilean regulatory sanitary agency issued a warning concerning dose adjustment and use restriction to avoid severe adverse effects of metoclopramide such tardive dyskinesia.

Aim: To study dyskinesia type adverse effects in a population using metoclopramide.

Material And Methods: A cross sectional observational study was conducted among patients pertaining to palliative care and diabetes mellitus programs and consuming 10 mg/day or more of metoclopramide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/s0034-98872018000700876DOI Listing

Setting the record straight: The nosology of tardive syndromes.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Department of Neurology, Loma Linda University Medical Center, Loma Linda, CA, USA.

We propose the use of the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements and the analogous repetitive movements of the limbs, trunk, or pelvis. The term tardive syndrome is an umbrella term to be used to refer to the spectrum of all persistent hyperkinetic, hypokinetic, and sensory phenomenologies resulting from chronic dopamine receptor blocking agent (DRBA) exposure. TD is a type of TS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.11.025DOI Listing
November 2018
1 Read

Quantitative DNA Methylation Analysis of DLGAP2 Gene using Pyrosequencing in Schizophrenia with Tardive Dyskinesia: A Linear Mixed Model Approach.

Sci Rep 2018 Nov 30;8(1):17466. Epub 2018 Nov 30.

Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, 100096, China.

Tardive dyskinesia (TD) is a side effect of antipsychotic medications used to treat schizophrenia (SCZ) and other mental health disorders. No study has previously used pyrosequencing to quantify DNA methylation levels of the DLGAP2 gene; while the quantitative methylation levels among CpG sites within a gene may be correlated. To deal with the correlated measures among three CpG sites within the DLGAP2 gene, this study analyzed DNA methylation levels of the DLGAP2 gene using a linear mixed model (LMM) in a Chinese sample consisting of 35 SCZ patients with TD, 35 SCZ without TD (NTD) and 34 healthy controls (HCs) collected in Beijing, China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35718-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269460PMC
November 2018
1 Read

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma.

Cureus 2018 Sep 24;10(9):e3349. Epub 2018 Sep 24.

Hematology and Oncology, University of Arizona, Tucson, USA.

Lenalidomide is commonly used as induction or maintenance therapy in multiple myeloma. We report a case of 71-year-old female presenting with tardive dyskinesia-like symptoms one month after starting her lenalidomide maintenance therapy after high-dose chemotherapy and autologous hematopoietic stem cell rescue. Her symptoms evolved over days to pronounced uncontrollable limb movements, tongue smacking, lip-smacking, abnormal sounds, and tongue biting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255714PMC
September 2018
1 Read

A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.

Agri 2018 Oct;30(4):199-201

Department of Anesthesiology and Reanimation, Zile State Hospital, Tokat, Turkey.

Tardive dyskinesia and tardive dystonia are caused by dopamine receptor blocking agents, mostly antipsychotics and sometimes antidepressants or calcium channel blockers. Duloxetine is a serotonin-noradrenaline reuptake inhibitor used in the treatment of diabetic neuropathic pain and fibromyalgia, as well as major depression. In this case, we aimed to discuss the tardive dyskinesia-like appearance of a patient using duloxetine due to fibromyalgia. Read More

View Article

Download full-text PDF

Source
October 2018
12 Reads

Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy.

Am J Geriatr Psychiatry 2019 Jan 14;27(1):84-90. Epub 2018 Sep 14.

Adult Neurodevelopment and Geriatric Psychiatry Division (PSA, TS, KP, BHM, TKR), Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry (PSA, TS, KP, BHM, TKR), University of Toronto, Toronto, Ontario, Canada.

Objective: Antipsychotic use in older patients is associated with many adverse effects, including tardive dyskinesia and extrapyramidal symptoms, which, in turn, increase the risk of falling. Antipsychotics are also associated with metabolic syndrome and cognitive impairment in older patients. Integrated care pathways (ICPs) are designed to manage specific conditions using standardized assessments and measurement-based interventions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10647481183048
Publisher Site
http://dx.doi.org/10.1016/j.jagp.2018.09.003DOI Listing
January 2019
3 Reads

Tardive Dyskinesia Should Not Be Overlooked.

J Child Adolesc Psychopharmacol 2018 Nov 2. Epub 2018 Nov 2.

1 Faculty of Medicine and Life Sciences, University of Tampere , Tampere, Finland .

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/cap.2018.0084
Publisher Site
http://dx.doi.org/10.1089/cap.2018.0084DOI Listing
November 2018
4 Reads

Changes in recruitment of motor cortex excitation and inhibition in patients with drug-induced tardive syndromes.

Neurophysiol Clin 2018 Oct 23. Epub 2018 Oct 23.

Sobell Department of Motor Neuroscience and movement Disorders, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Objectives: It has recently been suggested that drug-induced tardive syndromes (TS) might be due to maladaptive plasticity, which increases motor excitability in cerebral cortex and basal ganglia. In order to test this hypothesis, we performed the first measurements of cortical excitability in TS.

Methods: Motor cortex excitability was examined using transcranial magnetic stimulation (TMS) in 22 TS patients and compared with that in 20 age and sex-matched healthy individuals. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09877053183021
Publisher Site
http://dx.doi.org/10.1016/j.neucli.2018.10.001DOI Listing
October 2018
5 Reads

Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Drugs Aging 2018 11;35(11):959-971

Department of Neurology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9.100 SN, 28034, Madrid, Spain.

Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are iatrogenic consequences of antidopaminergic drugs. Both are particularly prevalent among the elderly and those with dementia. However, despite their prevalence, these disorders are often overlooked. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-018-0590-yDOI Listing
November 2018

[Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Nervenarzt 2018 Oct 19. Epub 2018 Oct 19.

Zentrum für Psychosoziale Medizin, Klinik für Allgemeine Psychiatrie, Universität Heidelberg, Heidelberg, Deutschland.

The treatment of schizophrenic psychoses with antipsychotic drugs (AP) is often associated with an increased risk of delayed occurrence of antipsychotic-associated movement disorders. Persistence and chronicity of such symptoms are very frequent. The risk of developing tardive dyskinesia (TD) is associated with the pharmacological effect profile of a particular AP, with treatment duration and age. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00115-018-0629-7
Publisher Site
http://dx.doi.org/10.1007/s00115-018-0629-7DOI Listing
October 2018
5 Reads

Lithium monotherapy-induced tardive dyskinesia.

J Affect Disord 2019 Feb 9;244:78-79. Epub 2018 Oct 9.

Laboratory of Clinical Neurophysiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Tardive dyskinesia is a movement disorder that develops during the course of long-term treatment with neuroleptic agents and is characterized primarily by choreiform and athetotic movements. We report the case of a 68-year old female suffering from Bipolar disorder, treated with lithium monotherapy 600 mg per day (serum levels 0.6) for the last 15 years. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01650327183211
Publisher Site
http://dx.doi.org/10.1016/j.jad.2018.10.094DOI Listing
February 2019
5 Reads

Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

J Neural Transm (Vienna) 2018 Oct 13. Epub 2018 Oct 13.

Sobell Department of Motor Neuroscience and Movement Disorders, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Tardive syndromes (TDS) typically manifest 3 months or later after exposure to antipsychotic drugs, and unfortunately have no satisfactory medical treatment. We explored the possibility of using therapeutic repetitive transcranial magnetic stimulation (rTMS). Twenty-six patients were allocated to receive real or sham rTMS over the hand/arm area of motor cortex (M1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-018-1941-xDOI Listing
October 2018
8 Reads

Diabetic gastroparesis: current challenges and future prospects.

Clin Exp Gastroenterol 2018 25;11:347-363. Epub 2018 Sep 25.

Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center, El Paso, TX, USA,

Diabetic gastroparesis (DMGP) is a condition of delayed gastric emptying after gastric outlet obstruction has been excluded. Symptoms of nausea, vomiting, early satiety, bloating, and abdominal pain are associated with DMGP. Uncontrolled symptoms can lead to overall poor quality of life and financial burdens on the healthcare system. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/diabetic-gastroparesis-current-cha
Publisher Site
http://dx.doi.org/10.2147/CEG.S131650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165730PMC
September 2018
2 Reads

VMAT2 Inhibitors in Neuropsychiatric Disorders.

CNS Drugs 2018 Dec;32(12):1131-1144

Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge St., 9th floor, Houston, TX, 77030, USA.

The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have recently gained more attention following their development for specific indications in the United States. At present, there are three commercially available VMAT2 inhibitors: tetrabenazine, deutetrabenazine, and valbenazine. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40263-018-0580-y
Publisher Site
http://dx.doi.org/10.1007/s40263-018-0580-yDOI Listing
December 2018
16 Reads

Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis.

Front Pharmacol 2018 18;9:974. Epub 2018 Sep 18.

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however, genetic factors play an important role. The Perlecan () gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.00974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157325PMC
September 2018
9 Reads

Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.

J Clin Psychiatry 2018 Sep 18;79(6). Epub 2018 Sep 18.

Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.

Objective: Tardive dyskinesia (TD) is an antipsychotic-induced movement disorder that typically occurs after long-term exposure to antipsychotic drugs. There is evidence that switching to clozapine reduces TD. This meta-analysis reviews the effect of switching to clozapine on the severity of TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.17r11852DOI Listing
September 2018
8 Reads

Acute dopamine receptor blockade in substantia nigra pars reticulata: a possible model for drug induced Parkinsonism.

J Neurophysiol 2018 Sep 26. Epub 2018 Sep 26.

Instituto de Fisiologia Celular, Universidad Nacional Autonoma de Mexico, Mexico.

Dopamine (DA) depletion modifies the firing pattern of neurons in the substantia nigra pars reticulata (SNr) shifting their mostly tonic firing towards irregularity and bursting, traits of pathological firing underlying rigidity and postural instability in Parkinson's disease (PD) patients and animal models of Parkinsonism (PS). Drug induced Parkinsonism (DIP) represents about 20-40% of clinical cases of PS becoming a problem for differential diagnosis, still not well studied with physiological tools. It may co-occur with tardive dyskinesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/jn.00579.2018DOI Listing
September 2018

Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial.

Brain Stimul 2018 Nov - Dec;11(6):1368-1377. Epub 2018 Sep 11.

Department of Neurology and Neurosurgery, Heinrich-Heine-University, Düsseldorf, Germany.

Introduction: Growing evidence suggests that pallidal deep brain stimulation represents a potential new therapeutic avenue in tardive dystonia/dyskinesia, but controlled and blinded randomized studies (RCT) are missing. The present RCT compares dystonia/dyskinesia severity of pallidal neurostimulation in patients with tardive dystonia using a delayed-start design paradigm.

Methods: Dystonia/dyskinesia severity was assessed via blinded videos following pallidal neurostimulation at 3 (blinded phase) and 6 months (open extension phase). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2018.08.006DOI Listing
September 2018
4 Reads

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.

BMC Psychiatry 2018 Sep 24;18(1):306. Epub 2018 Sep 24.

Teva Pharmaceutical Industries, 41 Moores Rd, Frazer, Malvern, PA, 19355, USA.

Background: Data are limited on the benefits and risks of dose reduction in managing side effects associated with antipsychotic treatment. As an example, antipsychotic dose reduction has been recommended in the management of tardive dyskinesia (TD), yet the benefits of lowering doses are not well studied. However, stable maintenance treatment is essential to prevent deterioration and relapse in schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12888-018-1889-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154822PMC
September 2018
1 Read

Uncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity via D2 Receptors.

Front Synaptic Neurosci 2018 7;10:31. Epub 2018 Sep 7.

School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, China.

Both Disrupted-In-Schizophrenia-1 (DISC1) and dopamine receptors D2R have significant contributions to the pathogenesis of schizophrenia. Our previous study demonstrated that DISC1 binds to D2R and such protein-protein interaction is enhanced in patients with schizophrenia and Disc1-L100P mouse model of schizophrenia (Su et al., 2014). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnsyn.2018.00031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137395PMC
September 2018
2 Reads

Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.

Brain Behav Immun 2018 Nov 11;74:241-251. Epub 2018 Sep 11.

Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Brazil.

The chronic use of drugs that reduce the dopaminergic neurotransmission can cause a hyperkinetic movement disorder called tardive dyskinesia (TD). The pathophysiology of this disorder is not entirely understood but could involve oxidative and neuroinflammatory mechanisms. Cannabidiol (CBD), the major non-psychotomimetic compound present in Cannabis sativa plant, could be a possible therapeutic alternative for TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbi.2018.09.014DOI Listing
November 2018
1 Read

Management of common adverse effects of antipsychotic medications.

World Psychiatry 2018 Oct;17(3):341-356

Department of Psychiatry, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.

The benefits of antipsychotic medications are sometimes obscured by their adverse effects. These effects range from relatively minor tolerability issues (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127750PMC
October 2018
2 Reads

Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.

World Psychiatry 2018 Oct;17(3):330-340

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.

Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial agonists (second-generation antipsychotics, SGAs) is considered significantly lower than with D2 antagonists (first-generation antipsychotics, FGAs). As some reports questioned this notion, we meta-analyzed randomized controlled studies (RCTs) to estimate the risk ratio (RR) and annualized rate ratio (RaR) of TD comparing SGAs vs. FGAs and SGAs vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127753PMC
October 2018
9 Reads

Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.

Tremor Other Hyperkinet Mov (N Y) 2018 31;8:570. Epub 2018 Aug 31.

Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Background: Although tardive dyskinesia (TD) is most commonly defined as a movement disorder caused by chronic exposure to dopamine-receptor-blocking drugs (DRBDs), it has also been thought to result from exposure to some non-DRBDs.

Methods: We critiqued many reviews making the association between non-DRBDs and a TD-like syndrome and almost all case reports. We checked whether cases met criteria for the diagnosis of TD-like syndrome and whether DRBDs had been excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/D8FF58Z9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125739PMC
November 2018

Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?

Authors:
Stephen M Stahl

CNS Spectr 2018 Aug;23(4):239-247

The two approved treatments for tardive dyskinesia both inhibit the vesicular monoamine transporter type 2 (VMAT2) yet have pharmacologic properties that distinguish one from the other. Knowing these differences may help optimize which treatment to select for individual patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852918001219DOI Listing
August 2018
8 Reads

Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement.

Sci Rep 2018 Aug 27;8(1):12884. Epub 2018 Aug 27.

Peking University HuiLongGuan Clinical Medical School, Beijing, P. R. China.

Tardive dyskinesia (TD) is a devastating motor disorder associated with the etiological process of schizophrenia or antipsychotic medication treatments. To examine whether cerebral morphological changes may manifest in TD, we used voxel-based morphometry to analyze high-resolution T1-weighted brain structural magnetic resonance images from 32 schizophrenics with TD (TD group), 31 schizophrenics without TD (non-TD group), and 32 healthy controls (HC group). We also assessed psychopathological symptoms with the Positive and Negative Syndrome Scale (PANSS), and TD severity with the Abnormal Involuntary Movement Scale (AIMS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-31186-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110787PMC
August 2018
10 Reads

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Nicotine Tob Res 2018 Aug 17. Epub 2018 Aug 17.

Center for Health Sciences, SRI International, Menlo Park, CA.

Implications: Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine and selective nAChR receptor agonists, reduce L-dopa-induced dyskinesias, as well as antipsychotic-induced tardive dyskinesia, and may be useful in Tourette's syndrome and ataxia. Subtype selective muscarinic cholinergic drugs may also provide effective therapies for Parkinson's disease, dyskinesias and dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ntr/nty063DOI Listing
August 2018
2 Reads

Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals.

Ann Pharmacother 2018 Aug 23:1060028018797110. Epub 2018 Aug 23.

1 University at Buffalo, Buffalo, NY, USA.

Objective: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018797110DOI Listing
August 2018
7 Reads

Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review.

CNS Drugs 2018 Oct;32(10):917-938

Department of Psychiatry, University of British Columbia, Room A3-111, 938 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.

Background: Although antipsychotics are used to treat Tourette syndrome, there have been reports of paradoxical induction of tics by first- and second-generation antipsychotics.

Objective: The objective of this systematic review was to better characterize tics as the potential adverse effect of antipsychotics.

Methods: A literature search was performed, with no language restriction, using the MEDLINE, EMBASE, and PsycINFO databases for all publications up to January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-018-0559-8DOI Listing
October 2018
1 Read
5.110 Impact Factor

Tardive Dyskinesia Suppression Seen During Catatonic State: A Case Report.

Psychosomatics 2018 Jul 29. Epub 2018 Jul 29.

Oklahoma State University Center for Health Sciences, Tulsa, OK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psym.2018.07.013DOI Listing
July 2018
1 Read

Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.

Neurosci Lett 2018 Nov 15;686:17-22. Epub 2018 Aug 15.

Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science Department, Campbell Family Mental Health Research Institute, CAMH, Canada; Institute of Medical Science, University of Toronto, Canada; Department of Psychiatry, University of Toronto, Canada; Laboratory Medicine and Pathobiology, University of Toronto, Canada. Electronic address:

Tardive dyskinesia (TD) is an involuntary movement disorder that occurs in ∼20% of patients after extended antipsychotic use. Its pathophysiology is unclear; however, familial patterns and gene association studies indicate an inherited component to risk. The disrupted in schizophrenia 1 (DISC1) gene was selected for analysis because it interacts with and regulates two important proteins involved in antipsychotic medication action: the dopamine D2 receptor and the cAMP phosphodiesterase type IVB (PDE4B). Read More

View Article

Download full-text PDF

Source
https://www.sciencedirect.com/journal/neuroscience-letters/v
Web Search
https://academic.oup.com/ntr/article-abstract/11/4/404/11007
Web Search
https://academic.oup.com/schizophreniabulletin/article/21/2/
Web Search
https://linkinghub.elsevier.com/retrieve/pii/S03043940183053
Publisher Site
http://dx.doi.org/10.1016/j.neulet.2018.08.007DOI Listing
November 2018
11 Reads

7-Methoxyderivative of tacrine is a 'foot-in-the-door' open-channel blocker of GluN1/GluN2 and GluN1/GluN3 NMDA receptors with neuroprotective activity in vivo.

Neuropharmacology 2018 Sep 9;140:217-232. Epub 2018 Aug 9.

Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic; Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic. Electronic address:

N-methyl-d-aspartate receptors (NMDARs) are ionotropic glutamate receptors that mediate excitatory neurotransmission in the mammalian central nervous system (CNS), and their dysregulation results in the aetiology of many CNS syndromes. Several NMDAR modulators have been used successfully in clinical trials (including memantine) and NMDARs remain a promising pharmacological target for the treatment of CNS syndromes. 1,2,3,4-Tetrahydro-9-aminoacridine (tacrine; THA) was the first approved drug for Alzheimer's disease (AD) treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2018.08.010DOI Listing
September 2018
5 Reads

Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.

Neurol Ther 2018 Dec 19;7(2):233-248. Epub 2018 Jul 19.

Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.

Introduction: Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement disorders associated with exposure to dopamine receptor blocking agents such as antipsychotics, but they differ in their pathophysiology and clinical management. Treatment for one may worsen the other, and there are important diagnostic clues that assist in making an accurate assessment and instituting a rational treatment plan.

Methods: A literature review was executed to identify articles relating to the presentation, pathophysiology, epidemiology, and management of DIP and TD. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40120-018-0105-0
Publisher Site
http://dx.doi.org/10.1007/s40120-018-0105-0DOI Listing
December 2018
2 Reads

Valbenazine and Deutetrabenazine for Tardive Dyskinesia.

Innov Clin Neurosci 2018 Jun;15(5-6):13-16

Dr. Touma is with the William Jennings Bryan Dorn VA Medical Center Community-based Outpatient Clinic in Anderson, South Carolina.

Tardive dyskinesia (TD) is a medication-induced permanent movement disorder with no United States Food and Drug Administration (FDA)-approved treatments prior to 2017. Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treatment of TD. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040721PMC
June 2018
8 Reads

[Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia].

Authors:
Sebastian Erbe

Fortschr Neurol Psychiatr 2018 Jul 11. Epub 2018 Jul 11.

Martin Gropius Krankenhaus GmbH, Klinik für Psychiatrie, Psychotherapie und Psychosomatik.

Tardive dyskinesias (TDs) are still common long-term sequelae of antipsychotic treatment. They are generally irreversible and associated with cognitive deficits, a decrease in quality of life and increased mortality. Furthermore, they potentially contribute to further stigmatization of the affected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0624-9368DOI Listing
July 2018
5 Reads

Tardive Akathisia with Asymmetric and Upper-body Presentation: Report of Two Cases and Literature Review.

Tremor Other Hyperkinet Mov (N Y) 2018 29;8:563. Epub 2018 May 29.

Department of Neurology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.

Background: Akathisia is an inner urge to move a body area with an objective motor component of restlessness. Tardive akathisia (TA) is usually bilateral with a predominant lower-body presentation. We report two patients with an asymmetrical predominantly upper-body involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/D8224B00DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026282PMC
November 2018
4 Reads

Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report.

Indian J Psychol Med 2018 Mar-Apr;40(2):189-190

Department of Psychiatry and NDDTC, AIIMS, New Delhi, India.

Tardive dyskinesia are known to occur commonly among patients receiving neuroleptic drugs for prolonged periods. But, few reports of acute onset dyskinesia have also been reported in the literature. This report highlights one such case where the patient had dyskinetic movements with a single low dose of oral Flupentixol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPSYM.IJPSYM_170_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008991PMC

Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia.

Authors:
Leslie Citrome

Evid Based Ment Health 2018 Aug 26;21(3):e12. Epub 2018 Jun 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/eb-2017-102825DOI Listing
August 2018
3 Reads

Prescription and Underprescription of Clozapine in Dutch Ambulatory Care.

Front Psychiatry 2018 11;9:231. Epub 2018 Jun 11.

Department of Psychosis Research, Rivierduinen Psychiatric Institute, Leiden, Netherlands.

To our knowledge, no study has examined in a structured way the extent of underprescription of clozapine in ambulatory patients with Non-Affective Psychotic Disorder (NAPD). In the Netherlands, psychiatric care for such patients is provided by Flexible Assertive Community Treatment (FACT) teams and by early intervention teams. In 20 FACT teams and 3 early intervention teams we assessed the proportion of patients who: use clozapine (type 1 patients), previously used this drug (type 2), have an unfulfilled indication for this drug, by type of indication (type 3), or were at least markedly psychotic, but had not yet received two adequate treatments with other antipsychotic drugs (type 4). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fpsyt.2018.00231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004504PMC
June 2018
9 Reads

Tardive Myoclonic Dyskinesia Responsive to Sodium Oxybate.

Clin Neuropharmacol 2018 Sep/Oct;41(5):194-196

Clinical Neurology Unit I, Department of Medicine, San Paolo University Hospital ASST Santi Paolo e Carlo.

Hyperkinetic movement disorders may be difficult to treat, but cases where patients respond to alcohol and/or drugs with similar effects have been described. We report the case of a 64-year-old man with tardive dyskinesia characterized by severe uncontrolled dystonic and myoclonic jerks of the face, shoulders, and arm and forearm muscles, which improved with oral sodium oxybate. Our case suggests the possibility to test sodium oxybate in patients with severe, drug-resistant hyperkinetic syndromes, especially when they are known to improve with alcohol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000290DOI Listing
December 2018
10 Reads

Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia.

JAMA Intern Med 2018 Aug;178(8):1110-1112

Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamainternmed.2018.2463DOI Listing
August 2018
23 Reads

[Diagnosis and treatment of motor phenomena in schizophrenia spectrum disorders].

Ther Umsch 2018 Jun;75(1):31-36

1 Universitätsklinik für Psychiatrie und Psychotherapie, Bern.

Diagnosis and treatment of motor phenomena in schizophrenia spectrum disorders Abstract. Motor abnormalities are intrinsic features of schizophrenia spectrum disorders. They may be spontaneous or antipsychotic drug-induced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/0040-5930/a000963DOI Listing

Resting-state Brain Activity Changes Associated with Tardive Dyskinesia in Patients with Schizophrenia: Fractional Amplitude of Low-frequency Fluctuation Decreased in the Occipital Lobe.

Neuroscience 2018 Aug 20;385:237-245. Epub 2018 Jun 20.

Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital 100096 Beijing, PR China. Electronic address:

We explored resting-state brain activity and its potential links to clinical parameters in schizophrenic patients with tardive dyskinesia (TD) using fractional amplitude of low-frequency fluctuations (fALFF). Resting-state functional magnetic resonance imaging data were acquired from 32 schizophrenic patients with TD (TD group), 31 without TD (NTD group), and 32 healthy controls (HC group). Clinical parameters including psychopathological symptoms, severity of TD, and cognitive function were assessed using the Positive and Negative Syndrome Scale, Abnormal Involuntary Movement Scale (AIMS), and Repeatable Battery for the Assessment of Neuropsychological Status, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroscience.2018.06.014DOI Listing
August 2018
23 Reads

Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia.

Int J Methods Psychiatr Res 2018 Dec 14;27(4):e1727. Epub 2018 Jun 14.

Department of Psychiatry, Affiliated WuTaiShan Hospital of Yangzhou University, Yangzhou, China.

Objectives: Many research indicate that the tardive dyskinesia (TD) is generally linked with long-term antipsychotic therapy for schizophrenia. Glial cell line-derived neurotrophic factor (GDNF) is a critical role in the protection of catecholaminergic, dopaminergic, and cholinergic neurons. Thus, we examined the serum GDNF levels in schizophrenia patients with TD (WTD) and without TD (NTD) and compared with healthy controls (HC), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mpr.1727DOI Listing
December 2018
10 Reads